Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Post by Jimpro63on Mar 02, 2020 11:46pm
128 Views
Post# 30759165

Vaxil Bio COVID19 vaccine candidate, patent-protected

Vaxil Bio COVID19 vaccine candidate, patent-protected

This Israel based biotech company announced that it has completed in silico analyses and believes that it has successfully identified a coronavirus vaccine candidate for the COVID-19 disease.

Vaxil Bio Ltd.’s vaccine candidate is based on unique and patent-protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform. 

Announced in a press release on February 14, 2020, this COVID-19 vaccine candidate’s design is based on successful in vivo experiments testing a tuberculosis signal peptide vaccine. 

“We are very excited to have been able to isolate a preliminary (vaccine) candidate that might address the current and emerging need in such a short time,” said David Goren, Vaxil’s Chairman, and Chief Executive Officer.

 

Mr. Goren continued to explain in this press release that “we have identified signal peptide combinations which we believe can be effective as a prophylactic vaccine against the current coronavirus and might also demonstrate therapeutic value in the future.”

Human coronaviruses were first identified in the mid-1960s. Coronaviruses are named for the crown-like spikes on their surface. 

 

Vaxil says it ‘exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatics approach.

These SPs induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. 

In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

 


Bullboard Posts